# Selective Transvenous Chemoembolization of Primary Pancreatic Tumors

> **NCT03865563** · PHASE1 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Retrograde venous infusion of gemcitabine/lipiodol

## Key facts

- **NCT ID:** NCT03865563
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07
- **Primary completion:** 2021-06
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** We need to make significant adjustments to proposed drug and its delivery method
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03865563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03865563, "Selective Transvenous Chemoembolization of Primary Pancreatic Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03865563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*